tetano
Editor, Senior Moderator
Rhinology
. 2022 Dec 8.
doi: 10.4193/Rhin22.223. Online ahead of print.
Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro
K Martens[SUP] 1 2 [/SUP], E Vanhulle[SUP] 3 [/SUP], A Viskens[SUP] 1 [/SUP], P W Hellings[SUP] 1 4 5 [/SUP], K Vermeire[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Disruption of the nasal epithelial barrier is believed to play a role in Coronavirus Disease-2019 (COVID-19) outcomes. Fluticasone propionate has been shown to restore the nasal epithelial barrier in allergic rhinitis to the level of healthy controls. The therapeutic potential of nasal steroid sprays in COVID-19 has recently been reported. However, further insight into the mode of action is warranted.
Objectives: To explore the in vitro mechanisms of the preventive potential of fluticasone propionate in SARS-CoV-2 infection.
Methods: Human air liquid interface cultures of Calu-3 cells and primary nasal epithelial cells isolated from healthy donors were used to investigate the preventive effect of fluticasone propionate on SARS-CoV-2 induced barrier disruption, virus replication and ACE2 expression.
Results: 48 hours pre-treatment with fluticasone propionate prevented the SARS-CoV-2 induced increase in fluorescein isothiocyanate-dextran 4 kDa permeability and reduced infection with SARS-CoV-2. Pre-treatment with fluticasone propionate also decreased ACE2 expression in SARS-CoV-2 infected Calu-3 cells.
Conclusion: Fluticasone propionate pre-treatment prevented SARS-CoV-2 increased epithelial permeability, reduced ACE2 expression and SARS-CoV-2 infection, underscoring the therapeutic potential of fluticasone propionate in the context of COVID-19.
. 2022 Dec 8.
doi: 10.4193/Rhin22.223. Online ahead of print.
Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro
K Martens[SUP] 1 2 [/SUP], E Vanhulle[SUP] 3 [/SUP], A Viskens[SUP] 1 [/SUP], P W Hellings[SUP] 1 4 5 [/SUP], K Vermeire[SUP] 3 [/SUP]
Affiliations
- PMID: 36479866
- DOI: 10.4193/Rhin22.223
Abstract
Background: Disruption of the nasal epithelial barrier is believed to play a role in Coronavirus Disease-2019 (COVID-19) outcomes. Fluticasone propionate has been shown to restore the nasal epithelial barrier in allergic rhinitis to the level of healthy controls. The therapeutic potential of nasal steroid sprays in COVID-19 has recently been reported. However, further insight into the mode of action is warranted.
Objectives: To explore the in vitro mechanisms of the preventive potential of fluticasone propionate in SARS-CoV-2 infection.
Methods: Human air liquid interface cultures of Calu-3 cells and primary nasal epithelial cells isolated from healthy donors were used to investigate the preventive effect of fluticasone propionate on SARS-CoV-2 induced barrier disruption, virus replication and ACE2 expression.
Results: 48 hours pre-treatment with fluticasone propionate prevented the SARS-CoV-2 induced increase in fluorescein isothiocyanate-dextran 4 kDa permeability and reduced infection with SARS-CoV-2. Pre-treatment with fluticasone propionate also decreased ACE2 expression in SARS-CoV-2 infected Calu-3 cells.
Conclusion: Fluticasone propionate pre-treatment prevented SARS-CoV-2 increased epithelial permeability, reduced ACE2 expression and SARS-CoV-2 infection, underscoring the therapeutic potential of fluticasone propionate in the context of COVID-19.